Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > December 20, 2022
Daily News
December 20, 2022
- Chugai Eyes Submission of Oral GLP-1 Agent in 2025-2026: R&D Briefing
December 20, 2022
- Kissei Won’t Change 2025 Targets Despite Linzagolix Setback, Decide US Plan by March
December 20, 2022
- LDP Health Panel OKs FY2023 Budget Plan; MHLW Gives “Low 300-Billion-Yen Range” for Drug Cost Cut
December 20, 2022
- Still No Serious Safety Concerns with COVID-19 Vaccines: MHLW Panels
December 20, 2022
- Japan Hospital Federation Calls for Drug Pricing Overhaul in FY2024
December 20, 2022
- LDP Lawmakers Give Certain Credit to FY2023 Price Revision Plan
December 20, 2022
- Susmed’s Insomnia App in Line for Approval as Early as January
December 20, 2022
- Enhertu Nabs EU Nod for Second-Line Gastric Cancer, CHMP OK for HER2 Low Breast Cancer
December 20, 2022
- Oncolys Keeps 2024 Target for Japan Telomelysin Filing; Partner Talks Ongoing
December 20, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…